米国企業
HUTCHMED (China) Ltd

HUTCHMED (China) LtdHCM

時価総額

PER

	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Goods	-	-	156	176	204	266	314	389
Commercialization Services	-	-	12	3	4	27	41	49
License & Collaborations-Services	-	-	18	16	10	19	24	80
Services-Research and Development	-	-	8	0	0	1	1	34
Other collaboration revenue-royalties	-	-	0	3	5	15	26	32
Other collaboration revenue-licensing	-	-	12	-	-	24	15	279
Services-commercialization	-	-	12	3	4	27	41	49
Services-research and development	-	-	8	0	0	1	1	34
Services-collaboration research and development	-	-	18	16	10	19	24	80
Other collaboration revenue-royalties	-	-	0	3	5	15	26	32
Other collaboration revenue-licensing	-	-	12	-	-	24	15	279
Revenue	216	241	214	205	228	356	426	838
Goods	-	-	129	153	179	229	269	332
Commercialization Services	-	-	9	2	6	26	39	48
Services-commercialization	-	-	9	2	6	26	39	48
Research and development expenses	67	76	114	138	175	299	387	302
Selling expenses	18	19	18	14	11	38	44	53
Administrative expenses	22	24	31	39	50	89	92	80
Total operating expenses	-	295	307	351	425	684	834	820
Income/(Loss) from operations	-47	-53	-93	-146	-197	-328	-408	18
Gain on divestment of an equity investee	-	-	-	-	-	121	-	-
Interest income	1	1	6	5	3	2	10	36
Other income	1	1	2	2	5	2	2	13
Interest expense	2	1	1	1	1	1	1	1
Other expense	-	1	1	0	0	13	14	8
Total other income/(expense)	-1	-0	6	5	7	-9	-3	40
Income/(loss) before income taxes and equity in earnings of equity investees	-47	-54	-87	-141	-190	-216	-410	58
Income tax (expense)/benefit	4	3	4	3	5	12	-0	5
Income (Loss) from Equity Method Investments	66	34	19	41	79	61	50	47
Net income/(loss)	15	-23	-71	-104	-116	-167	-360	101
Less: Net income attributable to non-controlling interests	3	4	4	2	10	28	0	0
Net income/(loss) attributable to the Company	15	-23	-71	-104	-116	-167	-360	101
Earnings Per Share, Basic	-	-0.43	-1.13	-	-	-0.25	-0.43	0.12
Earnings Per Share, Diluted	-	-0.43	-1.13	-	-	-0.25	-0.43	0.12